CN102300866B - 作为放射性药物的含氮大环共轭物 - Google Patents
作为放射性药物的含氮大环共轭物 Download PDFInfo
- Publication number
- CN102300866B CN102300866B CN200980156413.6A CN200980156413A CN102300866B CN 102300866 B CN102300866 B CN 102300866B CN 200980156413 A CN200980156413 A CN 200980156413A CN 102300866 B CN102300866 B CN 102300866B
- Authority
- CN
- China
- Prior art keywords
- group
- certain embodiments
- molecular recognition
- compound
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 NC(C*CCNC1)(CNCCNC2)CNCCNCC12N Chemical compound NC(C*CCNC1)(CNCCNC2)CNCCNCC12N 0.000 description 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/106—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from kidney or bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008906239A AU2008906239A0 (en) | 2008-12-02 | Radiopharmaceuticals | |
| AU2008906239 | 2008-12-02 | ||
| PCT/AU2009/001572 WO2010063069A1 (en) | 2008-12-02 | 2009-12-02 | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102300866A CN102300866A (zh) | 2011-12-28 |
| CN102300866B true CN102300866B (zh) | 2015-08-26 |
Family
ID=42232814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980156413.6A Active CN102300866B (zh) | 2008-12-02 | 2009-12-02 | 作为放射性药物的含氮大环共轭物 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US9701694B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2370447B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2012510477A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102300866B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009322081C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2745495C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3098225T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2712881T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010063069A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6207504B2 (ja) | 2011-07-07 | 2017-10-04 | オーストラリアン ニュークリア サイエンス アンド テクノロジー オーガニゼーション | クリプテート化合物 |
| WO2013082655A1 (en) * | 2011-12-06 | 2013-06-13 | The University Of Melbourne | Functionalisation of cage amine ligands for metallo-radiopharmaceuticals |
| DK2788353T3 (da) * | 2011-12-06 | 2022-08-15 | Clarity Pharmaceuticals Ltd | Bur-aminligander til metallo-radiofarmaceutika |
| US9422286B2 (en) | 2014-01-27 | 2016-08-23 | Washington University | Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease |
| GB201417067D0 (en) | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| WO2018081860A1 (en) * | 2016-11-04 | 2018-05-11 | Clarity Pharmaceuticals Pty Ltd | Formulations for radiotherapy and diagnostic imaging |
| CA3066525A1 (en) | 2017-06-06 | 2018-12-13 | The University Of Melbourne | Radiopharmaceuticals, radioimaging agents, and uses thereof |
| AU2019251769A1 (en) * | 2018-04-11 | 2020-10-15 | Clarity Pharmaceuticals Limited | Formulations and kits for radiotherapy and diagnostic imaging |
| CN111989324A (zh) * | 2018-04-11 | 2020-11-24 | 墨尔本大学 | 靶向化合物及其生产方法 |
| EP3976025A4 (en) * | 2019-05-24 | 2023-05-17 | Clarity Pharmaceuticals Limited | PSMA IMAGING AGENT FORMULATIONS |
| WO2021087568A1 (en) * | 2019-11-08 | 2021-05-14 | The University Of Queensland | Radiolabelled targeting ligands |
| WO2021150258A1 (en) * | 2020-01-26 | 2021-07-29 | Mainline Biosciences Llc | Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same |
| JP7894086B2 (ja) * | 2020-05-06 | 2026-07-23 | コーネル ユニヴァーシティー | 銅含有セラグノスティック化合物及びその使用の方法 |
| EP4196175A4 (en) * | 2020-08-14 | 2025-07-30 | Clarity Pharmaceuticals Ltd | RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION |
| AU2023322240A1 (en) * | 2022-08-11 | 2025-02-20 | Clarity Pharmaceuticals Limited | Dimeric radiopharmaceuticals, compositions thereof and uses thereof |
| CN116589508A (zh) * | 2023-05-16 | 2023-08-15 | 洛阳师范学院 | 一种基于半夹心铑构筑单元的矩形分子大环化合物及其制备方法和应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044095A (zh) * | 1988-06-24 | 1990-07-25 | 唐化学原料公司 | 大环双官能螯合剂、其配合物和它们的抗体共轭物 |
| WO1995031202A1 (en) * | 1994-05-17 | 1995-11-23 | Commonwealth Scientific And Industrial Research Organisation | Cage compounds, processes for their preparation and their use as antiviral agents |
| CN1152880A (zh) * | 1994-04-22 | 1997-06-25 | 孟山都公司 | 使用含氮大环配拉体的金属络合物的诊断图像分析的方法 |
| WO2003063912A1 (en) * | 2002-01-29 | 2003-08-07 | Bracco Imaging S.P.A. | Responsive paramagnetic mri contrast agents |
| WO2005037862A1 (en) * | 2003-10-17 | 2005-04-28 | Ctt Cancer Targeting Technologies Oy | Targeting compositions and preparation thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0001719A1 (en) | 1977-10-26 | 1979-05-02 | The Australian National University | Metal complexes, their preparation and production of hydrogen peroxide therewith |
| US5245055A (en) * | 1990-12-18 | 1993-09-14 | E. R. Squibb & Sons, Inc. | Process for preparing a cis oxabicyclo olefinic acid and ester from an oxabicyclo pyranol |
| JPH04244085A (ja) * | 1990-12-21 | 1992-09-01 | Doujin Kagaku Kenkyusho:Kk | 蛍光性化合物、錯体、試薬および該試薬を用いる特異的結合アッセイ |
| AUPP803899A0 (en) * | 1999-01-05 | 1999-01-28 | Australian National University, The | Cryptate compounds and methods for diagnosis and therapy. |
| US6107326A (en) | 1999-04-12 | 2000-08-22 | Cytopharm, Inc. | Porphycenes for treatment of microbial populations |
| GB0116815D0 (en) | 2001-07-10 | 2001-08-29 | Nycomed Amersham Plc | Improved chelator conjugates |
| WO2008147481A1 (en) * | 2007-02-09 | 2008-12-04 | Northeastern University | Precision-guided nanoparticle systems for drug delivery |
-
2009
- 2009-12-02 ES ES16172324T patent/ES2712881T3/es active Active
- 2009-12-02 US US13/132,194 patent/US9701694B2/en active Active
- 2009-12-02 EP EP09829884.7A patent/EP2370447B1/en active Active
- 2009-12-02 WO PCT/AU2009/001572 patent/WO2010063069A1/en not_active Ceased
- 2009-12-02 JP JP2011538797A patent/JP2012510477A/ja active Pending
- 2009-12-02 EP EP16172324.2A patent/EP3098225B1/en active Active
- 2009-12-02 CN CN200980156413.6A patent/CN102300866B/zh active Active
- 2009-12-02 CA CA2745495A patent/CA2745495C/en active Active
- 2009-12-02 AU AU2009322081A patent/AU2009322081C1/en active Active
- 2009-12-02 DK DK16172324.2T patent/DK3098225T3/en active
-
2015
- 2015-02-06 JP JP2015022109A patent/JP5981580B2/ja active Active
-
2017
- 2017-06-02 US US15/612,009 patent/US10544164B2/en active Active
- 2017-06-02 US US15/612,185 patent/US10301326B2/en active Active
-
2019
- 2019-04-09 US US16/378,716 patent/US10870664B2/en active Active
- 2019-12-12 US US16/712,485 patent/US11111254B2/en active Active
-
2021
- 2021-08-04 US US17/393,837 patent/US11905301B2/en active Active
-
2023
- 2023-10-31 US US18/498,744 patent/US12565506B2/en active Active
-
2026
- 2026-01-28 US US19/462,189 patent/US20260226078A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044095A (zh) * | 1988-06-24 | 1990-07-25 | 唐化学原料公司 | 大环双官能螯合剂、其配合物和它们的抗体共轭物 |
| CN1152880A (zh) * | 1994-04-22 | 1997-06-25 | 孟山都公司 | 使用含氮大环配拉体的金属络合物的诊断图像分析的方法 |
| WO1995031202A1 (en) * | 1994-05-17 | 1995-11-23 | Commonwealth Scientific And Industrial Research Organisation | Cage compounds, processes for their preparation and their use as antiviral agents |
| WO2003063912A1 (en) * | 2002-01-29 | 2003-08-07 | Bracco Imaging S.P.A. | Responsive paramagnetic mri contrast agents |
| WO2005037862A1 (en) * | 2003-10-17 | 2005-04-28 | Ctt Cancer Targeting Technologies Oy | Targeting compositions and preparation thereof |
Non-Patent Citations (1)
| Title |
|---|
| Functional Cage-Amine Complexes: Polymerisable Metallomonomers and Multi-Cage Complexes;Nigel A. Lengkeek;《PhD Thesis-University of Western Australia》;20071231;第200-201页Figure5.1、Figure5.2及Scheme 5.3,第202页5.3.1.1节及Scheme 5.4,第215-216页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170267699A1 (en) | 2017-09-21 |
| EP3098225A1 (en) | 2016-11-30 |
| US20240190897A1 (en) | 2024-06-13 |
| US20200115391A1 (en) | 2020-04-16 |
| US20210363161A1 (en) | 2021-11-25 |
| AU2009322081B2 (en) | 2016-05-26 |
| ES2712881T3 (es) | 2019-05-16 |
| US20110293517A1 (en) | 2011-12-01 |
| EP2370447B1 (en) | 2016-07-27 |
| CA2745495A1 (en) | 2010-06-10 |
| AU2009322081C1 (en) | 2016-09-01 |
| US12565506B2 (en) | 2026-03-03 |
| EP3098225B1 (en) | 2018-11-28 |
| JP5981580B2 (ja) | 2016-08-31 |
| JP2012510477A (ja) | 2012-05-10 |
| US9701694B2 (en) | 2017-07-11 |
| CN102300866A (zh) | 2011-12-28 |
| US20170267698A1 (en) | 2017-09-21 |
| EP2370447A4 (en) | 2013-08-14 |
| JP2015145367A (ja) | 2015-08-13 |
| AU2009322081A1 (en) | 2011-07-21 |
| US20260226078A1 (en) | 2026-08-06 |
| US11905301B2 (en) | 2024-02-20 |
| US20190225625A1 (en) | 2019-07-25 |
| CA2745495C (en) | 2017-07-18 |
| US10870664B2 (en) | 2020-12-22 |
| WO2010063069A1 (en) | 2010-06-10 |
| US10544164B2 (en) | 2020-01-28 |
| US11111254B2 (en) | 2021-09-07 |
| US10301326B2 (en) | 2019-05-28 |
| DK3098225T3 (en) | 2019-03-25 |
| EP2370447A1 (en) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12565506B2 (en) | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals | |
| JP6047581B2 (ja) | 金属放射性医薬品のためのケージアミン配位子 | |
| US9364570B2 (en) | Functionalisation of cage amine ligands for metallo-radiopharmaceuticals | |
| HK40080888A (en) | Cage amine ligands for metallo-radiopharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210621 Address after: Cornwallis street, Evely, NSW, Australia 2015 Patentee after: Transparent Medicine Co.,Ltd. Address before: Melbourne, Australia Patentee before: THE University OF MELBOURNE |
|
| TR01 | Transfer of patent right | ||
| CP02 | Change in the address of a patent holder |
Address after: 4 Cornwallis street, Evelyn, NSW, Australia 2015 Patentee after: Transparent Medicine Co.,Ltd. Address before: Cornwallis street, Evely, NSW, Australia 2015 Patentee before: Transparent Medicine Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder |